Petco Health and Wellness (WOOF) 10-Q 8 Dec 22 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Oct. 29, 2022	Dec. 06, 2022
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Oct. 29, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	Petco Health and Wellness Company, Inc.
Entity Central Index Key	0001826470
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--01-28
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Class A Common Stock, par value $0.001 per share
Trading Symbol	WOOF
Security Exchange Name	NASDAQ
Entity File Number	001-39878
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-1005932
Entity Address, Address Line One	10850 Via Frontera
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92127
City Area Code	858
Local Phone Number	453-7845
Document Quarterly Report	true
Document Transition Report	false
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		228,129,255
Class B-1 Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		37,790,781
Class B-2 Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		37,790,781

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Oct. 29, 2022	Jan. 29, 2022
Current assets:
Cash and cash equivalents	$ 148,731	$ 211,602
Receivables, less allowance for credit losses ($1,393 and $931, respectively)	46,446	55,618
Merchandise inventories, net	723,424	675,111
Prepaid expenses	43,708	42,355
Other current assets	56,724	86,091
Total current assets	1,019,033	1,070,777
Fixed assets	1,937,804	1,745,691
Less accumulated depreciation	(1,146,217)	(1,018,769)
Fixed assets, net	791,587	726,922
Operating lease right-of-use assets	1,378,336	1,338,465
Goodwill	2,191,891	2,183,991
Trade name	1,025,000	1,025,000
Other long-term assets	171,045	152,786
Total assets	6,576,892	6,497,941
Current liabilities:
Accounts payable and book overdrafts	384,595	403,976
Accrued salaries and employee benefits	125,113	150,630
Accrued expenses and other liabilities	220,055	210,872
Current portion of operating lease liabilities	304,789	265,897
Current portion of long-term debt and other lease liabilities	22,645	21,764
Total current liabilities	1,057,197	1,053,139
Senior secured credit facilities, net, excluding current portion	1,631,335	1,640,390
Operating lease liabilities, excluding current portion	1,131,081	1,096,133
Deferred taxes, net	298,380	318,355
Other long-term liabilities	130,990	134,105
Total liabilities	4,248,983	4,242,122
Commitments and contingencies (Notes 3 and 6)
Stockholders' equity:
Preferred stock, $0.001 par value: Authorized - 25.0 million shares; Issued and outstanding - none
Additional paid-in-capital	2,131,930	2,133,821
Retained earnings	200,235	142,166
Accumulated other comprehensive loss	(4,522)	(2,238)
Total stockholders’ equity	2,327,909	2,274,014
Noncontrolling interest		(18,195)
Total equity	2,327,909	2,255,819
Total liabilities and equity	6,576,892	6,497,941
Class A Common Stock
Stockholders' equity:
Common stock value	228	227
Class B-1 Common Stock
Stockholders' equity:
Common stock value	38	38
Class B-2 Common Stock
Stockholders' equity:
Common stock value

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Oct. 29, 2022	Jan. 29, 2022
Allowance for credit loss, current	$ 1,140	$ 931
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class A Common Stock
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares, issued	227,900,000	227,200,000
Common stock, shares, outstanding	227,900,000	227,200,000
Class B-1 Common Stock
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares, issued	37,800,000	37,800,000
Common stock, shares, outstanding	37,800,000	37,800,000
Class B-2 Common Stock
Common stock, par value per share	$ 0.000001	$ 0.000001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares, issued	37,800,000	37,800,000
Common stock, shares, outstanding	37,800,000	37,800,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021
Income Statement [Abstract]
Net sales	$ 1,501,220	$ 1,443,264	$ 4,458,008	$ 4,292,792
Cost of sales	903,543	848,555	2,658,180	2,501,688
Gross profit	597,677	594,709	1,799,828	1,791,104
Selling, general and administrative expenses	549,622	532,760	1,651,829	1,607,938
Operating income	48,055	61,949	147,999	183,166
Interest income	(130)	(18)	(287)	(53)
Interest expense	27,307	18,769	68,761	58,504
Loss on extinguishment and modification of debt	0	0	0	20,838
Other non-operating (income) loss	(576)	(19,773)	9,369	(64,934)
Income before income taxes and income from equity method investees	21,454	62,971	70,156	168,811
Income tax expense	4,161	14,095	20,799	43,784
Income from equity method investees	(2,627)	(2,637)	(7,821)	(7,490)
Net income	19,920	51,513	57,178	132,517
Net loss attributable to noncontrolling interest	0	(1,239)	(891)	(2,906)
Net income attributable to Class A and B-1 common stockholders	$ 19,920	$ 52,752	$ 58,069	$ 135,423
Net income per Class A and B-1 common share:
Basic	$ 0.07	$ 0.20	$ 0.22	$ 0.51
Diluted	$ 0.07	$ 0.20	$ 0.22	$ 0.51
Weighted average shares used in computing net income per Class A and B-1 common share:
Basic	265,689	264,228	265,390	264,220
Diluted	265,935	265,322	265,824	265,189

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 19,920	$ 51,513	$ 57,178	$ 132,517
Net loss attributable to noncontrolling interest	0	(1,239)	(891)	(2,906)
Net income attributable to Class A and B-1 common stockholders	19,920	52,752	58,069	135,423
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	89	(1,056)	(2,284)	(1,053)
Total other comprehensive income (loss), net of tax	89	(1,056)	(2,284)	(1,053)
Comprehensive income	20,009	50,457	54,894	131,464
Comprehensive loss attributable to noncontrolling interest	0	(1,239)	(891)	(2,906)
Comprehensive income attributable to Class A and B-1 common stockholders	$ 20,009	$ 51,696	$ 55,785	$ 134,370

CONSOLIDATED STATEMENTS OF EQUI

CONSOLIDATED STATEMENTS OF EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Common Stock Class A Common Stock	Common Stock Class B-1 Common Stock	Common Stock Class B-2 Common Stock	Additional Paid-in Capital	(Accumulated Deficit) Retained Earnings	Accumulated Other Comprehensive Loss	Total Stockholders'/Members' Equity	Noncontrolling Interest
Beginning Balance at Jan. 30, 2021	$ 2,055,265	$ 264				$ 2,092,110	$ (22,251)	$ (1,275)	$ 2,068,848	$ (13,583)
Beginning Balance (in shares) at Jan. 30, 2021			226,424	37,791	37,791
Equity-based compensation expense (Note 5)	11,604					11,604			11,604
Net income	6,149						7,560		7,560	(1,411)
Foreign currency translation adjustment, net of tax	(786)							(786)	(786)
Issuance of restricted stock awards (in shares)			55
Ending Balance at May. 01, 2021	2,072,232	264				2,103,714	(14,691)	(2,061)	2,087,226	(14,994)
Ending Balance (in shares) at May. 01, 2021			226,479	37,791	37,791
Beginning Balance at Jan. 30, 2021	2,055,265	264				2,092,110	(22,251)	(1,275)	2,068,848	(13,583)
Beginning Balance (in shares) at Jan. 30, 2021			226,424	37,791	37,791
Net income	132,517
Ending Balance at Oct. 30, 2021	2,220,913	264				2,126,294	113,172	(2,328)	2,237,402	(16,489)
Ending Balance (in shares) at Oct. 30, 2021			226,492	37,791	37,791
Beginning Balance at May. 01, 2021	2,072,232	264				2,103,714	(14,691)	(2,061)	2,087,226	(14,994)
Beginning Balance (in shares) at May. 01, 2021			226,479	37,791	37,791
Equity-based compensation expense (Note 5)	11,506					11,506			11,506
Net income	74,855						75,111		75,111	(256)
Foreign currency translation adjustment, net of tax	789							789	789
Issuance of restricted stock awards (in shares)			12
Ending Balance at Jul. 31, 2021	2,159,382	264				2,115,220	60,420	(1,272)	2,174,632	(15,250)
Ending Balance (in shares) at Jul. 31, 2021			226,491	37,791	37,791
Equity-based compensation expense (Note 5)	11,087					11,087			11,087
Net income	51,513						52,752		52,752	(1,239)
Foreign currency translation adjustment, net of tax	(1,056)							(1,056)	(1,056)
Issuance of common stock, net of tax withholdings	(13)					(13)			(13)
Issuance of common stock, net of tax withholdings (in shares)			1
Ending Balance at Oct. 30, 2021	2,220,913	264				2,126,294	113,172	(2,328)	2,237,402	(16,489)
Ending Balance (in shares) at Oct. 30, 2021			226,492	37,791	37,791
Beginning Balance at Jan. 29, 2022	2,255,819	265				2,133,821	142,166	(2,238)	2,274,014	(18,195)
Beginning Balance (in shares) at Jan. 29, 2022			227,187	37,791	37,791
Equity-based compensation expense (Note 5)	12,055					12,055			12,055
Net income	23,802						24,693		24,693	(891)
Foreign currency translation adjustment, net of tax	(1,598)							(1,598)	(1,598)
Issuance of common stock, net of tax withholdings	(2,371)					(2,371)			(2,371)
Issuance of common stock, net of tax withholdings (in shares)			291
Ending Balance at Apr. 30, 2022	2,287,707	265				2,143,505	166,859	(3,836)	2,306,793	(19,086)
Ending Balance (in shares) at Apr. 30, 2022			227,478	37,791	37,791
Beginning Balance at Jan. 29, 2022	2,255,819	265				2,133,821	142,166	(2,238)	2,274,014	(18,195)
Beginning Balance (in shares) at Jan. 29, 2022			227,187	37,791	37,791
Net income	57,178
Ending Balance at Oct. 29, 2022	2,327,909	266				2,131,930	200,235	(4,522)	2,327,909
Ending Balance (in shares) at Oct. 29, 2022			227,943	37,791	37,791
Beginning Balance at Apr. 30, 2022	2,287,707	265				2,143,505	166,859	(3,836)	2,306,793	(19,086)
Beginning Balance (in shares) at Apr. 30, 2022			227,478	37,791	37,791
Equity-based compensation expense (Note 5)	13,422					13,422			13,422
Net income	13,456						13,456		13,456
Foreign currency translation adjustment, net of tax	(775)							(775)	(775)
Investment in veterinary joint venture(Note 1)	(35,000)					(54,086)			(54,086)	$ 19,086
Issuance of common stock, net of tax withholdings	336	1				335			336
Issuance of common stock, net of tax withholdings (in shares)			431
Ending Balance at Jul. 30, 2022	2,279,146	266				2,103,176	180,315	(4,611)	2,279,146
Ending Balance (in shares) at Jul. 30, 2022			227,909	37,791	37,791
Equity-based compensation expense (Note 5)	16,069					16,069			16,069
Net income	19,920						19,920		19,920
Foreign currency translation adjustment, net of tax	89							89	89
Deferred tax effect of investment in veterinary joint venture (Note 1)	12,807					12,807			12,807
Issuance of common stock, net of tax withholdings	(122)					(122)			(122)
Issuance of common stock, net of tax withholdings (in shares)			34
Ending Balance at Oct. 29, 2022	$ 2,327,909	$ 266				$ 2,131,930	$ 200,235	$ (4,522)	$ 2,327,909
Ending Balance (in shares) at Oct. 29, 2022			227,943	37,791	37,791

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Oct. 29, 2022	Oct. 30, 2021
Cash flows from operating activities:
Net income	$ 57,178	$ 132,517
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	143,599	125,637
Amortization of debt discounts and issuance costs	3,694	4,579
Provision for deferred taxes	(6,413)	28,523
Equity-based compensation	40,892	36,491
Impairments, write-offs and losses on sale of fixed and other assets	2,299	5,918
Loss on extinguishment and modification of debt	0	20,838
Income from equity method investees	(7,821)	(7,490)
Non-cash operating lease costs	316,492	315,930
Other non-operating loss (income)	9,369	(64,934)
Changes in assets and liabilities:
Receivables	9,171	(3,652)
Merchandise inventories	(48,314)	(105,682)
Prepaid expenses and other assets	(2,536)	(8,053)
Accounts payable and book overdrafts	(19,381)	47,973
Accrued salaries and employee benefits	(16,160)	27,673
Accrued expenses and other liabilities	12,110	45,437
Operating lease liabilities	(282,954)	(314,620)
Other long-term liabilities	(1,762)	1,359
Net cash provided by operating activities	209,463	288,444
Cash flows from investing activities:
Cash paid for fixed assets	(212,074)	(164,330)
Cash paid for acquisitions, net of cash acquired	(7,750)	(3,545)
Cash paid for interest in veterinary joint venture	(35,000)	0
Proceeds from sale of assets	2,127	105
Net cash used in investing activities	(252,697)	(167,770)
Cash flows from financing activities:
Borrowings under long-term debt agreements	123,000	1,700,000
Repayments of long-term debt	(135,750)	(1,686,611)
Debt refinancing costs	0	(24,665)
Payments for finance lease liabilities	(4,174)	(2,650)
Proceeds from employee stock purchase plan and stock option exercises	3,472	2,920
Tax withholdings on stock-based awards	(13,581)	(13)
Payment of offering costs	0	(3,844)
Net cash used in financing activities	(27,033)	(14,863)
Net (decrease) increase in cash, cash equivalents and restricted cash	(70,267)	105,811
Cash, cash equivalents and restricted cash at beginning of year	221,890	119,540
Cash, cash equivalents and restricted cash at end of year	151,623	225,351
Supplemental cash flow disclosures:
Interest paid, net	59,608	47,006
Capitalized interest	954	642
Income taxes paid	9,598	13,718
Supplemental non-cash investing and financing activities disclosure:
Accounts payable and accrued expenses for capital expenditures	$ 33,107	$ 36,623

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Oct. 29, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1 . Summary of Significant Accounting Policies Basis of Presentation Petco Health and Wellness Company, Inc. (together with its consolidated subsidiaries, the “Company”) is a category-defining health and wellness company focused on improving the lives of pets, pet parents, and its own partners. The Company manages its business as one reportable operating segment. In the opinion of management, the accompanying consolidated financial statements contain all adjustments necessary for a fair presentation as prescribed by accounting principles generally accepted in the United States (“GAAP”). All adjustments were comprised of normal recurring adjustments, except as noted in these Notes to Consolidated Financial Statements. There have been no significant changes from the significant accounting policies disclosed in Note 1 of the Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended January 29, 2022. The accompanying consolidated financial statements have been prepared in accordance with GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year. The accompanying consolidated financial statements and these Notes to Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended January 29, 2022 , from which the prior year balance sheet information herein was derived. Use of Estimates The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. These estimates are based on information that is currently available and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions. Veterinary Joint Venture The Company previously held a 50 % investment in a joint venture with a domestic partner to build and operate veterinary clinics in Petco locations. The joint venture was a variable interest entity for which the Company was the primary beneficiary, and accordingly, the joint venture’s results of operations and statements of financial position are included in the Company’s consolidated financial statements. In May 2022, the Company completed the purchase of the remaining 50 % of the issued and outstanding membership interests of the joint venture, which is now a wholly owned subsidiary of the Company, for cash consideration of $ 35.0 million. Direct transaction costs related to this purchase were not material. During the third quarter of fiscal 2022, the tax effects of the purchase were finalized, which resulted in a redetermination of the related deferred tax balances in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 – Income Taxes. Derivative Instruments In November 2022, the Company entered into a series of interest rate cap agreements to limit the maximum interest on a portion of the Company’s variable-rate debt and decrease its exposure to interest rate variability when the three-month Secured Overnight Financing Rate as published by CME Group exceeds 4.5 %. The interest rate caps are forward-starting with an effective date of December 30, 2022 and expire on December 31, 2024 . Cash and Cash Equivalents The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets to the total amounts reported in the consolidated statements of cash flows (in thousands): October 29, January 29, Cash and cash equivalents $ 148,731 $ 211,602 Restricted cash included in other current assets 2,892 10,288 Total cash, cash equivalents and restricted cash in $ 151,623 $ 221,890 Recent Accounting Pronouncements In March 2020, the FASB issued Accounting Standards Update No. 2020-04 – Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships, and other transactions affected by the anticipated transition from LIBOR. As a result of the reference rate reform initiative, certain widely used reference rates such as LIBOR are expected to be discontinued. The guidance is designed to simplify how entities account for contracts, such as receivables, debt, leases, derivative instruments and hedging, that are modified to replace LIBOR or other benchmark interest rates with new rates. The guidance is effective upon issuance and may be applied through December 31, 2022. The Company is currently evaluating the impact of this accounting standard, but does not expect for it to have a material impact on the consolidated financial statements and related disclosures.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Oct. 29, 2022
Revenue From Contract With Customer [Abstract]
Revenue Recognition	2. Revenue Recognition Net sales by product type and services were as follows (in thousands): Thirteen weeks ended Thirty-nine weeks ended October 29, October 30, October 29, October 30, Consumables $ 720,512 $ 643,125 $ 2,093,510 $ 1,850,203 Supplies and companion animals 575,259 635,278 1,775,149 1,957,022 Services and other 205,449 164,861 589,349 485,567 Net sales $ 1,501,220 $ 1,443,264 $ 4,458,008 $ 4,292,792

Senior Secured Credit Facilitie

Senior Secured Credit Facilities	9 Months Ended
	Oct. 29, 2022
Debt Disclosure [Abstract]
Senior Secured Credit Facilities	3 . Senior Secured Credit Facilities The Company previously had a senior secured term loan facility (the “Amended Term Loan Facility”), which was fully repaid on March 4, 2021 , and a senior secured asset-based revolving credit facility (the “Amended Revolving Credit Facility”), which was terminated on March 4, 2021 . On March 4, 2021 , the Company entered into a $ 1,700.0 million secured term loan facility maturing on March 4, 2028 (the “First Lien Term Loan”) and a secured asset-based revolving credit facility with availability of up to $ 500.0 million, subject to a borrowing base, maturing on March 4, 2026 (the “ABL Revolving Credit Facility”). As of October 29, 2022 , the Company was in compliance with its covenants under the First Lien Term Loan and the ABL Revolving Credit Facility. Term Loan Facilities On March 4, 2021 , the Company entered into the First Lien Term Loan and repaid all outstanding principal and interest on the Amended Term Loan Facility. Interest on the First Lien Term Loan is based on, at the Company’s option, either a base rate or Adjusted LIBOR, subject to a 0.75 % floor, payable upon maturity of the LIBOR contract, in either case plus the applicable rate. The base rate is the greater of the bank prime rate, federal funds effective rate plus 0.5 % or Adjusted LIBOR plus 1.0 %. The applicable rate is 2.25 % per annum for a base rate loan or 3.25 % per annum for an Adjusted LIBOR loan. Principal and interest payments commenced on June 30, 2021 . Principal payments are $ 4.25 million quarterly. In connection with the March 4, 2021 transaction described above, the Company recognized a loss on debt extinguishment and modification of $ 19.6 million on the term loan facilities, which consisted of a $ 6.5 million write-off of unamortized debt discount and issuance costs on the Amended Term Loan Facility and $ 13.1 million of third-party expenses. Fees relating to the Company’s entry into the First Lien Term Loan consisted of arranger fees and other third-party expenses. Of those fees, $ 3.2 million was capitalized as debt issuance costs, along with $ 4.3 million of original issue discount. The remaining portion of original issue discount and debt issuance costs of the Amended Term Loan Facility previously capitalized is being amortized over the contractual term of the First Lien Term Loan to interest expense using the effective interest rate in effect on the date of issuance, as these amounts represent the portion that was not substantially modified. As of October 29, 2022, the outstanding principal balance of the First Lien Term Loan was $ 1,674.5 million ($ 1,652.2 million, net of the unamortized discount and debt issuance costs). As of January 29, 2022, the outstanding principal balance of the First Lien Term Loan was $ 1,687.3 million ($ 1,662.1 million, net of the unamortized discount and debt issuance costs). The weighted average interest rate on the borrowings outstanding was 7.0 % and 4.1 % as of October 29, 2022 and January 29, 2022, respectively. Debt issuance costs are being amortized over the contractual term to interest expense using the effective interest rate in effect at issuance. As of October 29, 2022 and January 29, 2022, the estimated fair value of the First Lien Term Loan was approximately $ 1,611.7 million and $ 1,687.3 million, respectively, based upon Level 2 fair value hierarchy inputs. Revolving Credit Facilities On March 4, 2021, the Company entered into the ABL Revolving Credit Facility and terminated the Amended Revolving Credit Facility. The ABL Revolving Credit Facility has availability of up to $ 500.0 million, subject to a borrowing base. Fees relating to the Company’s entry into the ABL Revolving Credit Facility consisted of arranger fees and other third-party expenses. Of those fees, $ 4.1 million was capitalized as debt issuance costs. Unamortized debt issuance costs of $ 1.2 million were written off and recognized as a loss on debt extinguishment and modification in connection with this transaction. The remaining portion of debt issuance costs of the Amended Revolving Credit Facility previously capitalized is being amortized over the contractual term of the ABL Revolving Credit Facility as these amounts represent the portion that was not substantially modified. As of October 29, 2022 and January 29, 2022 , no amounts were outstanding under the ABL Revolving Credit Facility. At October 29, 2022, $ 443.9 million was available under the ABL Revolving Credit Facility, which is net of $ 56.1 million of outstanding letters of credit issued in the normal course of business and no borrowing base reduction for a shortfall in qualifying assets. Unamortized debt issuance costs of $ 3.9 million relating to the ABL Revolving Credit Facility were outstanding and were being amortized using the straight-line method over the remaining term of the agreement as of October 29, 2022. Unamortized debt issuance costs of $ 4.7 million relating to the ABL Revolving Credit Facility were outstanding and were being amortized using the straight-line method over the remaining term of the agreement as of January 29, 2022. The ABL Revolving Credit Facility has availability of up to $ 500.0 million and a $ 150.0 million letter of credit sub-facility. The availability is limited to a borrowing base, which allows borrowings of up to 90 % of eligible accounts receivable plus 90 % of the net orderly liquidation value of eligible inventory plus up to $ 50.0 million of qualified cash of the Company to which the Company and guarantors have no access, less reserves as determined by the administrative agent. Letters of credit reduce the amount available to borrow under the ABL Revolving Credit Facility by their face value. Interest on the ABL Revolving Credit Facility is based on, at the Company’s option, either the base rate or Adjusted LIBOR subject to a floor of 0 %, in either case, plus an applicable margin. The applicable margin is currently equal to 25 basis points in the case of base rate loans and 125 basis points in the case of Adjusted LIBOR loans. The applicable margin is adjusted quarterly based on the average historical excess availability as a percentage of the Line Cap, which represents the lesser of the aggregate ABL Revolving Credit Facility and the borrowing base, as follows: Average Historical Excess Availability Applicable Applicable Less than 33.3 % of the Line Cap 1.75 % 0.75 % Less than 66.7 % but greater than or equal to 33.3 % of 1.50 % 0.50 % Greater than or equal to 66.7 % of the Line Cap 1.25 % 0.25 % The ABL Revolving Credit Facility is subject to an unused commitment fee. If the actual daily utilized portion exceeds 50%, the unused commitment fee is 0.25 %. Otherwise, the unused commitment fee is 0.375 % and is not dependent upon excess availability.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Oct. 29, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	4 . Fair Value Measurements Assets and Liabilities Measured on a Recurring Basis The following table presents information about assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value (in thousands): October 29, 2022 Level 1 Level 2 Level 3 Assets (liabilities): Money market mutual funds $ 88,416 $ — $ — Investments of officers' life insurance $ — $ 12,041 $ — Non-qualified deferred compensation plan $ — $ ( 17,252 ) $ — Investment in Rover Group, Inc. $ 23,449 $ — $ — January 29, 2022 Level 1 Level 2 Level 3 Assets (liabilities): Money market mutual funds $ 167,277 $ — $ — Investments of officers' life insurance $ — $ 14,575 $ — Non-qualified deferred compensation plan $ — $ ( 17,453 ) $ — Investment in Rover Group, Inc. $ 32,819 $ — $ — The fair value of money market mutual funds is based on quoted market prices, such as quoted net asset values published by the fund as supported in an active market. Money market mutual funds included in the Company’s cash and cash equivalents were $ 86.5 million and $ 158.0 million as of October 29, 2022 and January 29, 2022, respectively. Also included in the Company’s money market mutual funds balances were $ 1.9 million and $ 9.3 million as of October 29, 2022 and January 29, 2022, respectively, which relate to the Company’s restricted cash, and are included in other current assets in the consolidated balance sheets. The Company maintains a deferred compensation plan for key executives and other members of management, which is funded by investments in officers’ life insurance. The fair value of this obligation is based on participants’ elected investments, which reflect the closing market prices of similar assets. The Company previously held an equity investment, in the form of multiple series of preferred stock, in A Place for Rover, Inc., an online marketplace for pet care, which was historically accounted for as an equity security without a readily determinable fair value. In July 2021, A Place for Rover, Inc. completed a business combination with Nebula Caravel Acquisition Corp., a publicly-traded special purpose acquisition company. The combined entity was renamed to Rover Group, Inc. (“Rover”), and the Company’s equity investment was converted into shares of Rover Class A common stock. In September 2021, the Company received additional shares of Rover Class A common stock in accordance with certain earnout provisions from the July 2021 business combination. The Company now remeasures the fair value of its investment on a quarterly basis, and the resulting gains or losses are included in other non-operating income in the consolidated statements of operations. On November 23, 2021, the Company completed the sale of approximately 11 % of its Rover Class A common stock for net proceeds of $ 6.1 million in cash as part of its participation in an underwritten secondary offering by certain Rover shareholders. In February 2022, the Company amended a collaboration agreement with a vendor, and as part of the amendment the Company was granted a right to receive equity and warrants for common shares of the vendor that is subject to certain performance conditions and other contingencies. The Company evaluated the agreement under FASB ASC 705-20, Consideration Received from a Vendor, and no material consideration was recognized during the thirty-nine week period ended October 29, 2022. Assets Measured on a Non-Recurring Basis The Company’s non-financial assets, which primarily consist of goodwill, other intangible assets, fixed assets and equity and other investments, are reported at carrying value, or at fair value as of the date of the Company’s acquisition of Petco Holdings, Inc. LLC on January 26, 2016, and are not required to be measured at fair value on a recurring basis. However, on a periodic basis (at least annually for goodwill and indefinite-lived intangibles or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable), non-financial assets are assessed for impairment. If impaired, the carrying values of the assets are written down to fair value using Level 3 inputs. There were no triggering events identified and no indication of impairment of the Company’s goodwill, indefinite-lived trade name, other intangible assets or equity and other investments during the thirteen or thirty-nine week periods ended October 29, 2022 and October 30, 2021. During the thirteen and thirty-nine week periods ended October 29, 2022, the Company recorded fixed asset and right-of-use asset impairment charges of $ 0.8 million and $ 1.8 million, respectively. During the thirteen and thirty-nine week periods ended October 30, 2021, the Company recorded fixed asset and right-of-use asset impairment charges of $ 2.9 million and $ 5.4 million, respectively.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Oct. 29, 2022
Stockholders Equity Note [Abstract]
Stockholders' Equity	5 . Stockholders’ Equity Equity-Based Compensation Equity-based compensation awards under the Company’s current equity incentive plan (the “2021 Equity Incentive Plan”) include restricted stock units (“RSUs,” which include performance-based stock units), restricted stock awards (“RSAs”), non-qualified stock options, and other equity compensation awards. The Company also has an employee stock purchase plan (“ESPP”). The Company’s controlling parent, Scooby LP, also maintains an incentive plan (the “2016 Incentive Plan”) under which it has awarded partnership unit awards to certain current and former employees, consultants, and non-employee directors of the Company that are restricted profit interests in Scooby LP subject to a distribution threshold (“Series C Units”). The following table summarizes the Company’s equity-based compensation expense by award type (in thousands): Thirteen weeks ended Thirty-nine weeks ended October 29, October 30, October 29, October 30, RSUs and RSAs $ 9,602 $ 6,189 $ 24,759 $ 19,013 Options 1,820 1,892 5,666 6,029 ESPP 315 343 927 734 Other awards 4,038 4,957 9,540 10,715 Total equity-based compensation expense $ 15,775 $ 13,381 $ 40,892 $ 36,491 Activity under the 2021 Equity Incentive Plan was as follows (shares and dollars in thousands): RSUs and RSAs Options Nonvested/outstanding, January 29, 2022 2,587 3,327 Granted 5,411 503 Vested and delivered/exercised ( 1,040 ) ( 45 ) Forfeited/expired ( 766 ) ( 475 ) Nonvested/outstanding, October 29, 2022 6,192 3,310 Unrecognized compensation expense as of October 29, 2022 $ 85,405 $ 10,681 Weighted average remaining expense period as of October 29, 2022 2.3 Years 1.6 Years RSA activity has not been material and relates to an RSA of Class A common stock granted to an executive in March 2021. For this grant, 50 % of the RSA becomes vested on each of the first two anniversaries of the grant date. Unvested RSAs are not considered participating securities for earnings per share purposes, as any related dividends are forfeitable. The ESPP allows eligible employees to contribute up to 15 % of their base earnings towards purchases of Class A common stock, subject to an annual maximum. The purchase price will be 85 % of the lower of (i) the fair market value of the stock on the associated lookback date and (ii) the fair market value of the stock on the last day of the related purchase period. Series C Unit activity under the 2016 Incentive Plan was as follows (in thousands): Units Outstanding, January 29, 2022 207,178 Granted — Forfeited ( 5,701 ) Outstanding, October 29, 2022 201,477 Vested, October 29, 2022 148,225 No additional Series C Units have been or will be awarded following the Company’s initial public offering. As of October 29, 2022, unrecognized compensation expense related to the unvested portion of Scooby LP’s Series C Units was $ 10.8 million, which is expected to be recognized over a weighted average period of 1.5 years. In addition to acceleration upon a change in control, a portion of grantees’ Series C Units may vest upon certain levels of direct or indirect sales by Scooby LP of the Company’s Class A common stock, and all unvested Series C Units will fully accelerate in the event Scooby LP sells 90 % or more of its direct or indirect holdings of the Company’s Class A common stock. Earnings (Loss) Per Share Potentially dilutive securities include potential Class A common shares related to outstanding stock options, unvested RSUs and RSAs, and the ESPP, calculated using the treasury stock method. The calculation of diluted shares outstanding excludes securities where the combination of the exercise or purchase price (in the case of options and the ESPP) and the associated unrecognized compensation expense is greater than the average market price of Class A common shares because the inclusion of these securities would be anti-dilutive. There were approximately 5.3 million and 3.5 million potential shares that were anti-dilutive and excluded from the computation of diluted shares outstanding during the thirty-nine weeks ended October 29, 2022 and October 30, 2021 , respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 29, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	6 . Commitments and Contingencies The Company is involved in legal proceedings and is subject to other claims and litigation, in each case, arising in the ordinary course of its business. The Company has made accruals with respect to certain of these matters, where appropriate, which are reflected in the Company’s consolidated financial statements but are not, individually or in the aggregate, considered material. For other matters, the Company has not made accruals because management has not yet determined that a loss is probable or because the amount of loss cannot be reasonably estimated. While the ultimate outcome of the matters cannot be determined, the Company currently does not expect that these matters will have a material adverse effect on its consolidated financial statements. The outcome of any litigation is inherently uncertain, however, and if decided adversely to the Company, or if the Company determines that settlement of particular litigation is appropriate, the Company may be subject to liability that could have a material adverse effect on its consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 29, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Petco Health and Wellness Company, Inc. (together with its consolidated subsidiaries, the “Company”) is a category-defining health and wellness company focused on improving the lives of pets, pet parents, and its own partners. The Company manages its business as one reportable operating segment. In the opinion of management, the accompanying consolidated financial statements contain all adjustments necessary for a fair presentation as prescribed by accounting principles generally accepted in the United States (“GAAP”). All adjustments were comprised of normal recurring adjustments, except as noted in these Notes to Consolidated Financial Statements. There have been no significant changes from the significant accounting policies disclosed in Note 1 of the Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended January 29, 2022. The accompanying consolidated financial statements have been prepared in accordance with GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year. The accompanying consolidated financial statements and these Notes to Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended January 29, 2022 , from which the prior year balance sheet information herein was derived.
Use of Estimates	Use of Estimates The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. These estimates are based on information that is currently available and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.
Veterinary Joint Venture	Veterinary Joint Venture The Company previously held a 50 % investment in a joint venture with a domestic partner to build and operate veterinary clinics in Petco locations. The joint venture was a variable interest entity for which the Company was the primary beneficiary, and accordingly, the joint venture’s results of operations and statements of financial position are included in the Company’s consolidated financial statements. In May 2022, the Company completed the purchase of the remaining 50 % of the issued and outstanding membership interests of the joint venture, which is now a wholly owned subsidiary of the Company, for cash consideration of $ 35.0 million. Direct transaction costs related to this purchase were not material. During the third quarter of fiscal 2022, the tax effects of the purchase were finalized, which resulted in a redetermination of the related deferred tax balances in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 – Income Taxes.
Derivative Instruments	Derivative Instruments In November 2022, the Company entered into a series of interest rate cap agreements to limit the maximum interest on a portion of the Company’s variable-rate debt and decrease its exposure to interest rate variability when the three-month Secured Overnight Financing Rate as published by CME Group exceeds 4.5 %. The interest rate caps are forward-starting with an effective date of December 30, 2022 and expire on December 31, 2024 .
Cash and Cash Equivalents	Cash and Cash Equivalents The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets to the total amounts reported in the consolidated statements of cash flows (in thousands): October 29, January 29, Cash and cash equivalents $ 148,731 $ 211,602 Restricted cash included in other current assets 2,892 10,288 Total cash, cash equivalents and restricted cash in $ 151,623 $ 221,890
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2020, the FASB issued Accounting Standards Update No. 2020-04 – Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships, and other transactions affected by the anticipated transition from LIBOR. As a result of the reference rate reform initiative, certain widely used reference rates such as LIBOR are expected to be discontinued. The guidance is designed to simplify how entities account for contracts, such as receivables, debt, leases, derivative instruments and hedging, that are modified to replace LIBOR or other benchmark interest rates with new rates. The guidance is effective upon issuance and may be applied through December 31, 2022. The Company is currently evaluating the impact of this accounting standard, but does not expect for it to have a material impact on the consolidated financial statements and related disclosures.
Goodwill and Intangible Assets Impairment	The Company’s non-financial assets, which primarily consist of goodwill, other intangible assets, fixed assets and equity and other investments, are reported at carrying value, or at fair value as of the date of the Company’s acquisition of Petco Holdings, Inc. LLC on January 26, 2016, and are not required to be measured at fair value on a recurring basis. However, on a periodic basis (at least annually for goodwill and indefinite-lived intangibles or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable), non-financial assets are assessed for impairment. If impaired, the carrying values of the assets are written down to fair value using Level 3 inputs.
Earnings (Loss) Per Share	Earnings (Loss) Per Share Potentially dilutive securities include potential Class A common shares related to outstanding stock options, unvested RSUs and RSAs, and the ESPP, calculated using the treasury stock method. The calculation of diluted shares outstanding excludes securities where the combination of the exercise or purchase price (in the case of options and the ESPP) and the associated unrecognized compensation expense is greater than the average market price of Class A common shares because the inclusion of these securities would be anti-dilutive.
Litigation	The Company is involved in legal proceedings and is subject to other claims and litigation, in each case, arising in the ordinary course of its business. The Company has made accruals with respect to certain of these matters, where appropriate, which are reflected in the Company’s consolidated financial statements but are not, individually or in the aggregate, considered material. For other matters, the Company has not made accruals because management has not yet determined that a loss is probable or because the amount of loss cannot be reasonably estimated. While the ultimate outcome of the matters cannot be determined, the Company currently does not expect that these matters will have a material adverse effect on its consolidated financial statements. The outcome of any litigation is inherently uncertain, however, and if decided adversely to the Company, or if the Company determines that settlement of particular litigation is appropriate, the Company may be subject to liability that could have a material adverse effect on its consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Oct. 29, 2022
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets to the total amounts reported in the consolidated statements of cash flows (in thousands): October 29, January 29, Cash and cash equivalents $ 148,731 $ 211,602 Restricted cash included in other current assets 2,892 10,288 Total cash, cash equivalents and restricted cash in $ 151,623 $ 221,890

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Oct. 29, 2022
Revenue From Contract With Customer [Abstract]
Summary of Net Sales by Product Type and Services	Net sales by product type and services were as follows (in thousands): Thirteen weeks ended Thirty-nine weeks ended October 29, October 30, October 29, October 30, Consumables $ 720,512 $ 643,125 $ 2,093,510 $ 1,850,203 Supplies and companion animals 575,259 635,278 1,775,149 1,957,022 Services and other 205,449 164,861 589,349 485,567 Net sales $ 1,501,220 $ 1,443,264 $ 4,458,008 $ 4,292,792

Senior Secured Credit Facilit_2

Senior Secured Credit Facilities (Tables)	9 Months Ended
	Oct. 29, 2022
Debt Disclosure [Abstract]
Applicable Margin for Adjusted LIBOR Loans and Base Rate Loans based on Average Historical Excess Availability	The applicable margin is adjusted quarterly based on the average historical excess availability as a percentage of the Line Cap, which represents the lesser of the aggregate ABL Revolving Credit Facility and the borrowing base, as follows: Average Historical Excess Availability Applicable Applicable Less than 33.3 % of the Line Cap 1.75 % 0.75 % Less than 66.7 % but greater than or equal to 33.3 % of 1.50 % 0.50 % Greater than or equal to 66.7 % of the Line Cap 1.25 % 0.25 %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Oct. 29, 2022
Fair Value Disclosures [Abstract]
Schedule of Information About Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents information about assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value (in thousands): October 29, 2022 Level 1 Level 2 Level 3 Assets (liabilities): Money market mutual funds $ 88,416 $ — $ — Investments of officers' life insurance $ — $ 12,041 $ — Non-qualified deferred compensation plan $ — $ ( 17,252 ) $ — Investment in Rover Group, Inc. $ 23,449 $ — $ — January 29, 2022 Level 1 Level 2 Level 3 Assets (liabilities): Money market mutual funds $ 167,277 $ — $ — Investments of officers' life insurance $ — $ 14,575 $ — Non-qualified deferred compensation plan $ — $ ( 17,453 ) $ — Investment in Rover Group, Inc. $ 32,819 $ — $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Oct. 29, 2022
Stockholders Equity Note [Abstract]
Summary of Equity-based Compensation Expense by Award Type	The following table summarizes the Company’s equity-based compensation expense by award type (in thousands): Thirteen weeks ended Thirty-nine weeks ended October 29, October 30, October 29, October 30, RSUs and RSAs $ 9,602 $ 6,189 $ 24,759 $ 19,013 Options 1,820 1,892 5,666 6,029 ESPP 315 343 927 734 Other awards 4,038 4,957 9,540 10,715 Total equity-based compensation expense $ 15,775 $ 13,381 $ 40,892 $ 36,491
Schedule of Nonvested Share Activity	Activity under the 2021 Equity Incentive Plan was as follows (shares and dollars in thousands): RSUs and RSAs Options Nonvested/outstanding, January 29, 2022 2,587 3,327 Granted 5,411 503 Vested and delivered/exercised ( 1,040 ) ( 45 ) Forfeited/expired ( 766 ) ( 475 ) Nonvested/outstanding, October 29, 2022 6,192 3,310 Unrecognized compensation expense as of October 29, 2022 $ 85,405 $ 10,681 Weighted average remaining expense period as of October 29, 2022 2.3 Years 1.6 Years
Schedule of Series C Unit Activity Under 2016 Incentive Plan	Series C Unit activity under the 2016 Incentive Plan was as follows (in thousands): Units Outstanding, January 29, 2022 207,178 Granted — Forfeited ( 5,701 ) Outstanding, October 29, 2022 201,477 Vested, October 29, 2022 148,225

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) $ in Millions	1 Months Ended		9 Months Ended
	Nov. 30, 2022	May 31, 2022 USD ($)	Oct. 29, 2022 Segment
Summary Of Significant Accounting Policies [Line Items]
Number of reportable segments			1
Number of operating segments			1
Subsequent Event
Summary Of Significant Accounting Policies [Line Items]
Derivative, cap interest rate	4.50%
Derivative, effective date	Dec. 30, 2022
Derivative, maturity date	Dec. 31, 2024
Variable Interest Entities, Primary Beneficiary
Summary Of Significant Accounting Policies [Line Items]
Ownership percentage			50%
Percentage of remaining ownership interest purchased in variable interest entity		50%
Cash consideration | $		$ 35

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Oct. 29, 2022	Jan. 29, 2022
Accounting Policies [Abstract]
Cash and cash equivalents	$ 148,731	$ 211,602
Restricted cash included in other current assets	$ 2,892	$ 10,288
Restricted Cash and Cash Equivalents, Asset, Statement of Financial Position [Extensible List]	Other current assets	Other current assets
Total cash, cash equivalents and restricted cash in the statement of cash flows	$ 151,623	$ 221,890

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Sales by Product Type and Services (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021
Disaggregation Of Revenue [Line Items]
Net sales	$ 1,501,220	$ 1,443,264	$ 4,458,008	$ 4,292,792
Consumables
Disaggregation Of Revenue [Line Items]
Net sales	720,512	643,125	2,093,510	1,850,203
Supplies and companion animals
Disaggregation Of Revenue [Line Items]
Net sales	575,259	635,278	1,775,149	1,957,022
Services and other
Disaggregation Of Revenue [Line Items]
Net sales	$ 205,449	$ 164,861	$ 589,349	$ 485,567

Senior Secured Credit Facilit_3

Senior Secured Credit Facilities - Additional Information (Details) - USD ($)		3 Months Ended		9 Months Ended
	Mar. 04, 2021	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021	Jan. 29, 2022
Line Of Credit Facility [Line Items]
Credit facility, covenant compliance				the Company was in compliance with its covenants under the First Lien Term Loan and the ABL Revolving Credit Facility.
Loss on debt extinguishment		$ 0	$ 0	$ 0	$ (20,838,000)
Letter of credit sub facility		150,000,000		$ 150,000,000
Maximum borrowing capacity of eligible accounts receivable in percentage				90%
Borrowing capacity of net orderly liquidation value of eligible inventory in percentage				90%
Qualified cash		50,000,000		$ 50,000,000
Amended Term Loan Facility
Line Of Credit Facility [Line Items]
Credit facility, maturity date	Mar. 04, 2021
Loss on debt extinguishment	$ (19,600,000)
Write-off of unamortized debt discount and issuance costs	6,500,000
Debt issuance cost related to third party expenses	$ 13,100,000
Outstanding principal balance, gross						$ 1,687,300,000
Outstanding principal balance, net of unamortized discount and debt issuance costs						$ 1,662,100,000
Weighted average interest rate						4.10%
Amended Term Loan Facility | Level 2
Line Of Credit Facility [Line Items]
Estimated fair value of credit facility						$ 1,687,300,000
First Lien Term Loan
Line Of Credit Facility [Line Items]
Credit facility, initiation date	Mar. 04, 2021
Borrowings under credit facility	$ 1,700,000,000
Credit facility, maturity date	Mar. 04, 2028
Debt instrument floor rate	0.75%
Quarterly principal payments	$ 4,250,000
Principal and interest payments commencement date	Jun. 30, 2021
Arranger fees and other third party expenses capitalized as debt issuance costs	$ 3,200,000
Debt original issue discount	$ 4,300,000
Outstanding principal balance, gross		1,674,500,000		1,674,500,000
Outstanding principal balance, net of unamortized discount and debt issuance costs		$ 1,652,200,000		$ 1,652,200,000
Weighted average interest rate		7%		7%
First Lien Term Loan | Level 2
Line Of Credit Facility [Line Items]
Estimated fair value of credit facility		$ 1,611,700,000		$ 1,611,700,000
First Lien Term Loan | Base Rate
Line Of Credit Facility [Line Items]
Debt instrument basis spread on variable rate	0.50%
Applicable annual rate	2.25%
First Lien Term Loan | Adjusted LIBOR
Line Of Credit Facility [Line Items]
Debt instrument basis spread on variable rate	1%
Applicable annual rate	3.25%
Amended Revolving Credit Facility
Line Of Credit Facility [Line Items]
Credit facility, maturity date	Mar. 04, 2021
Outstanding principal balance, net of unamortized discount and debt issuance costs						0
Unamortized debt issuance costs						$ 4,700,000
ABL Revolving Credit Facility
Line Of Credit Facility [Line Items]
Credit facility, initiation date	Mar. 04, 2021
Borrowings under credit facility	$ 500,000,000
Credit facility, maturity date	Mar. 04, 2026
Debt instrument floor rate				0%
Arranger fees and other third party expenses capitalized as debt issuance costs	$ 4,100,000
Outstanding principal balance, net of unamortized discount and debt issuance costs		0		$ 0
Unamortized debt issuance costs	$ 1,200,000	3,900,000		3,900,000
Borrowings available under credit facility		443,900,000		443,900,000
Outstanding letters of credit		56,100,000		56,100,000
Borrowings base reduction		$ 0		0
Maximum borrowing capacity				$ 500,000,000
Line of credit facility, unused commitment fee percentage				0.375%
ABL Revolving Credit Facility | Actual Daily Utilized Portion Exceeds 50%
Line Of Credit Facility [Line Items]
Line of credit facility, unused commitment fee percentage				0.25%
ABL Revolving Credit Facility | Base Rate
Line Of Credit Facility [Line Items]
Debt instrument basis spread on variable rate				0.25%
ABL Revolving Credit Facility | London Interbank Offered Rate (LIBOR)
Line Of Credit Facility [Line Items]
Debt instrument basis spread on variable rate				1.25%

Senior Secured Credit Facilit_4

Senior Secured Credit Facilities - Applicable Margin for Adjusted LIBOR Loans and Base Rate Loans based on Average Historical Excess Availability (Details) - ABL Revolving Credit Facility	9 Months Ended
	Oct. 29, 2022
Applicable Margin for Adjusted LIBOR Loans
Line Of Credit Facility [Line Items]
Applicable Margin Rate for Loans based on Average Historical Excess Availability	1.25%
Applicable Margin for Adjusted LIBOR Loans | Less than 33.3% of the Line Cap
Line Of Credit Facility [Line Items]
Applicable Margin Rate for Loans based on Average Historical Excess Availability	1.75%
Applicable Margin for Adjusted LIBOR Loans | Less than 66.7% but Greater than or Equal to 33.3% of the Line Cap
Line Of Credit Facility [Line Items]
Applicable Margin Rate for Loans based on Average Historical Excess Availability	1.50%
Applicable Margin for Adjusted LIBOR Loans | Greater than or Equal to 66.7% of the Line Cap
Line Of Credit Facility [Line Items]
Applicable Margin Rate for Loans based on Average Historical Excess Availability	1.25%
Applicable Margin for Base Rate Loans
Line Of Credit Facility [Line Items]
Applicable Margin Rate for Loans based on Average Historical Excess Availability	0.25%
Applicable Margin for Base Rate Loans | Less than 33.3% of the Line Cap
Line Of Credit Facility [Line Items]
Applicable Margin Rate for Loans based on Average Historical Excess Availability	0.75%
Applicable Margin for Base Rate Loans | Less than 66.7% but Greater than or Equal to 33.3% of the Line Cap
Line Of Credit Facility [Line Items]
Applicable Margin Rate for Loans based on Average Historical Excess Availability	0.50%
Applicable Margin for Base Rate Loans | Greater than or Equal to 66.7% of the Line Cap
Line Of Credit Facility [Line Items]
Applicable Margin Rate for Loans based on Average Historical Excess Availability	0.25%

Senior Secured Credit Facilit_5

Senior Secured Credit Facilities - Applicable Margin for Adjusted LIBOR Loans and Base Rate Loans based on Average Historical Excess Availability (Parenthetical) (Details) - ABL Revolving Credit Facility	9 Months Ended
	Oct. 29, 2022
Less than 33.3% of the Line Cap | Applicable Margin for Adjusted LIBOR Loans | Maximum
Line Of Credit Facility [Line Items]
Percentage of average historical excess availability of loans	33.30%
Less than 33.3% of the Line Cap | Applicable Margin for Base Rate Loans | Maximum
Line Of Credit Facility [Line Items]
Percentage of average historical excess availability of loans	33.30%
Less than 66.7% but Greater than or Equal to 33.3% of the Line Cap | Applicable Margin for Adjusted LIBOR Loans | Maximum
Line Of Credit Facility [Line Items]
Percentage of average historical excess availability of loans	66.70%
Less than 66.7% but Greater than or Equal to 33.3% of the Line Cap | Applicable Margin for Adjusted LIBOR Loans | Minimum
Line Of Credit Facility [Line Items]
Percentage of average historical excess availability of loans	33.30%
Less than 66.7% but Greater than or Equal to 33.3% of the Line Cap | Applicable Margin for Base Rate Loans | Maximum
Line Of Credit Facility [Line Items]
Percentage of average historical excess availability of loans	66.70%
Less than 66.7% but Greater than or Equal to 33.3% of the Line Cap | Applicable Margin for Base Rate Loans | Minimum
Line Of Credit Facility [Line Items]
Percentage of average historical excess availability of loans	33.30%
Greater than or Equal to 66.7% of the Line Cap | Applicable Margin for Adjusted LIBOR Loans | Minimum
Line Of Credit Facility [Line Items]
Percentage of average historical excess availability of loans	66.70%
Greater than or Equal to 66.7% of the Line Cap | Applicable Margin for Base Rate Loans | Minimum
Line Of Credit Facility [Line Items]
Percentage of average historical excess availability of loans	66.70%

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Information About Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($) $ in Thousands	Oct. 29, 2022	Jan. 29, 2022
Level 1 | Money Market Mutual Funds
Assets (liabilities):
Asset fair value	$ 88,416	$ 167,277
Level 1 | Investments of Officers' Life Insurance
Assets (liabilities):
Asset fair value	0	0
Level 1 | Investment in Rover Group, Inc.
Assets (liabilities):
Asset fair value	23,449	32,819
Level 2 | Money Market Mutual Funds
Assets (liabilities):
Asset fair value	0	0
Level 2 | Investments of Officers' Life Insurance
Assets (liabilities):
Asset fair value	12,041	14,575
Level 2 | Investment in Rover Group, Inc.
Assets (liabilities):
Asset fair value	0	0
Level 3 | Money Market Mutual Funds
Assets (liabilities):
Asset fair value	0	0
Level 3 | Investments of Officers' Life Insurance
Assets (liabilities):
Asset fair value	0	0
Level 3 | Investment in Rover Group, Inc.
Assets (liabilities):
Asset fair value	0	0
Non-qualified Deferred Compensation Plan | Level 1
Assets (liabilities):
Liabilities fair value	0	0
Non-qualified Deferred Compensation Plan | Level 2
Assets (liabilities):
Liabilities fair value	(17,252)	(17,453)
Non-qualified Deferred Compensation Plan | Level 3
Assets (liabilities):
Liabilities fair value	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
	Nov. 23, 2021	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021	Jan. 29, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Impairment of fixed asset and right-of-use asset		$ 0.8	$ 2.9	$ 1.8	$ 5.4
Cash and Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Money market mutual funds		86.5		86.5		$ 158
Restricted Cash | Other Current Assets
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Money market mutual funds		$ 1.9		$ 1.9		$ 9.3
Investment in Rover Group, Inc. | Class A Common Stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of common stock sold	11%
Net proceeds from sale of common stock	$ 6.1

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Equity-based Compensation Expense by Award Type (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 29, 2022	Oct. 30, 2021	Oct. 29, 2022	Oct. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total equity-based compensation expense	$ 15,775	$ 13,381	$ 40,892	$ 36,491
RSUs and RSAs
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total equity-based compensation expense	9,602	6,189	24,759	19,013
Options
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total equity-based compensation expense	1,820	1,892	5,666	6,029
ESPP
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total equity-based compensation expense	315	343	927	734
Other Awards
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total equity-based compensation expense	$ 4,038	$ 4,957	$ 9,540	$ 10,715

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Nonvested Share Activity (Details) - 2021 Equity Incentive Plan shares in Thousands, $ in Thousands	9 Months Ended
	Oct. 29, 2022 USD ($) shares
RSUs and RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested/outstanding, January 29, 2022	2,587
Granted	5,411
Vested and delivered/exercised	(1,040)
Forfeited/expired	(766)
Nonvested/outstanding, October 29, 2022	6,192
Unrecognized compensation expense as of October 29, 2022 | $	$ 85,405
Weighted average remaining expense period as of October 29, 2022	2 years 3 months 18 days
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, January 30, 2021	3,327
Granted	503
Options exercised	(45)
Forfeited/expired	(475)
Options outstanding, October 30, 2021	3,310
Unrecognized compensation expense as of October 30, 2021 | $	$ 10,681
Weighted average remaining expense period as of October 29, 2022	1 year 7 months 6 days

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Mar. 31, 2021	Oct. 29, 2022	Oct. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Anti-dilutive shares excluded from computation of diluted shares outstanding		5,300,000	3,500,000
2016 Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of additional shares awarded		0
Unrecognized compensation expense related to the unvested portion		$ 10.8
Weighted average period for recognition		1 year 6 months
Class A Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee stock purchase plan maximum percentage of earnings to purchase shares by eligible participants		15%
Purchase price as a percentage of the lesser of the market value of such shares at either the lookback date or last day of related purchase period		85%
Class A Common Stock | 2016 Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Threshold percentage of direct and indirect holdings of common stock		90%
Class A Common Stock | Executive
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	2 years
Class A Common Stock | First Two Anniversaries of Grant Date | Executive
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of restricted shares vested	50%

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Series C Unit Activity Under 2016 Incentive Plan (Details) - 2016 Incentive Plan	9 Months Ended
	Oct. 29, 2022 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding, January 29, 2022	207,178,000
Granted	0
Forfeited	(5,701,000)
Outstanding, October 29, 2022	201,477,000
Vested, October 29, 2022	148,225,000